Jun 23, 2026, 05:55 UTC
The European Commission approved Sanofi's Cenrifki for treating non-relapsing secondary progressive multiple sclerosis in adults.
Source:Jun 23, 2026, 05:15 UTC
Japan's Ministry of Health, Labour and Welfare granted marketing and manufacturing authorization to Sanofi's Wayrilz for the treatment of immune thrombocytopenia.
Source:Jun 22, 2026, 14:22 UTC
Bionyra Pharma launched and raised €143 million in an oversubscribed Series A financing round co-led by Jeito Capital and Sofinnova Partners, with participation from Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Health Ventures.
Source:Jun 18, 2026, 12:00 UTC
COUR Pharma closed a $50 million Series B financing round led by Lumira Ventures and Roche Venture Fund with new investment from Sanofi.
Source:Jun 15, 2026, 17:15 UTC
Sanofi received FDA approval to expand the use of Tzield in children with newly diagnosed stage 3 type 1 diabetes.
Source:Jun 13, 2026, 13:22 UTC
The FDA approved teplizumab, a type 1 diabetes drug developed by Sanofi, for children aged 8 and older with stage 3 diabetes.
Source:Jun 12, 2026, 22:09 UTC
Sanofi's Tzield received US approval as the first disease-modifying therapy for recently diagnosed stage 3 type 1 diabetes patients.
Source:Jun 10, 2026, 15:51 UTC
Kymera Therapeutics starts patient dosing in a phase I study of KT-485 for hidradenitis suppurativa, triggering a $20 million milestone payment from Sanofi.
Source:Jun 10, 2026, 14:31 UTC
Sanofi halted a Phase 3 study of its drug riliprubart after an interim analysis showed the therapy was not effective.
Jun 4, 2026, 09:55 UTC
Sanofi launched its 2026 global employee stock purchase plan, Action 2026, offering shares at a 20% discount to approximately 75,000 employees across 52 countries.
Source:
← PreviousPage 2